Arul M Chinnaiyan
S P Hicks Endowed Professor of Pathology
Section Head
Michigan Center for Translational Pathology
Professor of Pathology
Professor of Urology
[email protected]

Available to mentor
Arul M Chinnaiyan
Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Precision Health Initiative
    • Center Member
      Taubman Institute
    • Center Member
      Rogel Cancer Center
    • Center Member
      Center for Computational Medicine and Bioinformatics
    Recent Publications See All Publications
    • Journal Article
      Corrigendum to 'Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment' Neoplasia, Volume 22, Issue 2 (2020) 111-119.
      Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, McCollum BL, Wilder-Romans K, Apel IJ, Cao X, Speers C, Wang S, Chinnaiyan AM. Neoplasia, 2024 May; 51: 100986 DOI:10.1016/j.neo.2024.100986
      PMID: 38492449
    • Journal Article
      Corrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330].
      Choi JE, Verhaegen ME, Yazdani S, Malik R, Harms PW, Mangelberger D, Tien J, Cao X, Wang Y, Cieślik M, Gurkan J, Yazdani M, Jing X, Juckette K, Su F, Wang R, Zhou B, Apel IJ, Wang S, Dlugosz AA, Chinnaiyan AM. Neoplasia, 2024 May; 51: 100995 DOI:10.1016/j.neo.2024.100995
      PMID: 38574506
    • Journal Article
      MP41-02 COMBINING SERUM PROSTATE HEALTH INDEX WITH URINARY PCA3 AND TMPRSS2:ERG RNA TESTING IMPROVES DETECTION OF CLINICALLY-SIGNIFICANT PROSTATE CANCER
      Narayan VM, Eyrich N, Huang E, Zheng Y, Wei J, Sokoll L, Chan D, Patil D, Chinnaiyan A, Tomlins SA, Lotan Y, Lin D, Scherr D, Kibel A, Taneja SS, Bidair M, Thompson IM, Sanda MG. Journal of Urology, 2024 May; 211 (5S): e673 DOI:10.1097/01.ju.0001008896.93851.5b.02
    • Journal Article
      Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
      Chen Z, Wang M, Wu D, Zhao L, Metwally H, Jiang W, Wang Y, Bai L, McEachern D, Luo J, Wang M, Li Q, Matvekas A, Wen B, Sun D, Chinnaiyan AM, Wang S. J Med Chem, 2024 Apr 11; 67 (7): 5351 - 5372. DOI:10.1021/acs.jmedchem.3c01789
      PMID: 38530938
    • Journal Article
      Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
      He T, Cheng C, Qiao Y, Cho H, Young E, Mannan R, Mahapatra S, Miner SJ, Zheng Y, Kim N, Zeng VZ, Wisniewski JP, Hou S, Jackson B, Cao X, Su F, Wang R, Chang Y, Kuila B, Mukherjee S, Dukare S, Aithal KB, D S S, Abbineni C, Vaishampayan U, Lyssiotis CA, Parolia A, Xiao L, Chinnaiyan AM. Proc Natl Acad Sci U S A, 2024 Apr 9; 121 (15): e2322563121 DOI:10.1073/pnas.2322563121
      PMID: 38557192
    • Preprint
      Integrated cancer cell-specific single-cell RNA-seq datasets of immune checkpoint blockade-treated patients.
      Gondal MN, Cieslik M, Chinnaiyan AM. 2024 Apr 3; DOI:10.1101/2024.01.17.576110
      PMID: 38328153
    • Preprint
      p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
      Luo J, Chen Z, Qiao Y, Ching-Yi Tien J, Young E, Mannan R, Mahapatra S, He T, Eyunni S, Zhang Y, Zheng Y, Su F, Cao X, Wang R, Cheng Y, Seri R, George J, Shahine M, Miner SJ, Vaishampayan U, Wang M, Wang S, Parolia A, Chinnaiyan AM. 2024 Mar 30; DOI:10.1101/2024.03.29.587346
      PMID: 38586029
    • Preprint
      NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.
      Parolia A, Eyunni S, Verma BK, Young E, Liu L, George J, Aras S, Das CK, Mannan R, Rasool RU, Luo J, Carson SE, Mitchell-Velasquez E, Liu Y, Xiao L, Gajjala PR, Jaber M, Wang X, He T, Qiao Y, Pang M, Zhang Y, Alhusayan M, Cao X, Tavana O, Hou C, Wang Z, Ding K, Chinnaiyan AM, Asangani IA. 2024 Mar 29; DOI:10.1101/2024.02.22.581560
      PMID: 38464251